Acute graft-versus-host disease is still a major cause of transplant-related mortality after allogeneic stem cell transplantation. It requires immunosuppressive treatments that broadly abrogate T cell responses, including beneficial ones directed against tumor cells or infective pathogens. Inhibition of the heat shock protein of 90 kDa has been demonstrated to eliminate tumor cells, as well as alloreactive T cells while preserving antiviral T cell immunity. Here, we show that the suppressive effects of heat shock protein of 90 kDa inhibition on alloreactive T cells were synergistically enhanced by concomitant inhibition of the PI3K/Akt signaling pathway, which is also strongly activated upon allogeneic stimulation. Molecular analyses revealed that this antiproliferative effect was mainly mediated by induction of cell-cycle arrest and apoptosis. In addition, we observed an increased proportion of activated regulatory T cells, which critically contribute to acute graft-versus-host disease control, upon combined heat shock protein of 90 kDa/Akt isoforms 1 and 2 or heat shock protein of 90 kDa/PI3K/p110d isoform inhibition. Moreover, antiviral T cell immunity was functionally preserved after combined heat shock protein of 90 kDa/Akt isoforms 1 and 2 inhibition. Taken together, our data suggest that the combined heat shock protein of 90 kDa/PI3K/Akt inhibition approach represents a reasonable dual strategy to suppress residual tumor growth and efficiently deplete alloreactive T cells and thus, provide a rationale to prevent and treat acute graft-versus-host disease selectively without impairing pathogen-specific T cell immunity.
Introduction
ASCT has become a proven treatment modality for patients with hematologic malignancies, such as leukemias or MM. Whereas a subset of alloreactive donor T cells mediates the desired immunologic GvL effect, other alloreactive donor T cell subsets directed against host antigens can provoke aGvHD, an unwanted overshooting immune response mostly affecting the liver, skin, and gastrointestinal tract and frequently causing transplantrelated mortality [1] . Current anti-aGvHD strategies, such as pharmacological immunosuppression or T cell depletion, can attenuate aGvHD-associated inflammation but unselectively affect all activated T cells, including T allo , directed against tumor cells, as well as pathogen-specific T cells. Such treatments are always a trade-off between the benefits of aGvHD suppression and the resulting immunodeficiency, which promotes tumor relapse and entails an abundance of opportunistic infections [2, 3] . Therapeutic strategies that reduce the activity of host-reactive donor T cells while preserving the GvL effect and pathogen-specific T cell responses would be highly desirable to improve the tolerability and efficacy of ASCT.
We have shown previously that inhibition of the molecular chaperone Hsp90 abrogates molecular signaling, reduces proliferation, und induces apoptosis predominantly in T allo , whereas antiviral T cell immunity remains fully preserved [4] . In addition to its role in activated T cells, Hsp90 has been experimentally identified as an anti-cancer target, suggesting that pharmacological Hsp90 inhibition could serve as a reasonable dual therapeutic strategy to eradicate minimal residual disease and to control aGvHD. However, increasing experimental data and first clinical experiences suggest that pharmacological Hsp90 inhibitors should be combined with other targeted approaches to avoid adverse toxicities while maintaining strong anti-cancer potency [5] . Several signaling pathways, such as Jak/STAT, Ras/ MAPK, or PI3K/Akt, are critically involved in proper T cell activation and differentiation and require stabilization of their key components by Hsp90-mediated chaperoning [6] [7] [8] . Inhibitors of these pathways thus represent reasonable combination partners with Hsp90 inhibitors. We hypothesize that concomitant Hsp90/Akt inhibition might be a suitable approach, as the Ser/Thr kinase Akt is a bona fide Hsp90 client protein, and its activity critically contributes to the malignant growth of tumor cells [9, 10] . Moreover, inhibition of PI3K/Akt signaling has been reported to synergize with Hsp90 inhibition in preclinical tumor models [11, 12] . In an attempt to improve the anti-Hsp90 approach further, we evaluated the concomitant inhibition of Hsp90 and PI3Kd or Akt 1/2 in T allo as a potential, novel strategy to combine selective aGvHD suppression and tumor treatment.
MATERIALS AND METHODS

Antibodies and reagents
DMAG was provided by Invivogen (Toulouse, France), Akti was provided by Merck Millipore (Schwalbach am Taunus, Germany), and Cal was provided by Selleckchem (Munich, Germany). rhGM-CSF, rhIL-4, rhTNF-a, rhIL-6, and rhIL-1b were all purchased from R&D Systems (Wiesbaden, Germany); PGE 2 was purchased from Sigma (Munich, Germany); and ZVAD was purchased from PeptaNova (Sandhausen, Germany). Primary mAb and pAb were obtained from the following sources: anti-CD3z (1D4, mouse mAb), PerCPconjugated anti-CD4 (SK3), Pacific blue-conjugated anti-CD8 (RPA-T8), FITC-conjugated anti-CD25 (2A3), APC-conjugated anti-CD25 (M-A251), APC-conjugated anti-CD40 (5C3), PE-conjugated anti-CD86 (2331, FUN-1), PE-Cy7-conjugated anti-CD127 (HIL-7R-M21), FITC-conjugated anti-DC-SIGN (DCN-46), Alexa 647-conjugated anti-FoxP3 (259D/C7), and anti-phospho CD3z (Tyr142; K25-407.69, mouse mAb) from BD Biosciences (Heidelberg, Germany); Brilliant Violet 510-conjugated anti-CD4 (OKT4), PE-conjugated anti-LAP (TW4-2F8), and PE-conjugated anti-LAP (FNLAP) from eBioscience (Frankfurt, Germany); anti-Akt1 (2H10, mouse mAb), anti-Akt2 (5B5, rabbit mAb), anti-Akt3 (62A8, rabbit mAb), anti-ERK (pAb, rabbit), anti-MEK1/2 (pAb, rabbit), anti-pan-Akt (rabbit pAb), anti-phospho-Akt (Ser473; 193H12, rabbit mAb), anti-phospho-Akt (Thr308; rabbit pAb), anti-phospho ERK1/2 (Thr202/Tyr204; rabbit pAb), anti-phospho MEK1/2 (Ser217/221; 41G9, rabbit mAb), anti-phospho-FoxO1 (Thr24)/3a (Thr32; rabbit pAb), antiphospho-Rb (Ser807/811; rabbit pAb), anti-phospho ZAP70 [Tyr319/Syk (Tyr352); rabbit pAb], anti-p21 WAF1/CIP1 (12D1, rabbit mAb), anti-p27 Kip1 (SX53G8.5, mouse mAb), anti-PARP (rabbit pAb), anti-Rb (4H1, mouse mAb), and anti-ZAP70 (99F2, rabbit mAb) from Cell Signaling Technology (Frankfurt, Germany); anti-HSP72 from Enzo Life Sciences (Lörrach, Germany); anti-p53 (DO-1, mouse mAb) and anti-Raf1 (C-12, rabbit pAb) from Santa Cruz Biotechnology (Heidelberg, Germany); and anti-b-actin (AC-15, mouse mAb) and anti-Vinculin (clone VIN-11-5, mouse mAb) from Sigma. Anti-Hsp90a (HSP86) and anti-Hsp90b (HSP84) were from Merck Millipore. Secondary HRP-conjugated anti-rabbit antibody was obtained from Life Technologies (Darmstadt, Germany), HRP-conjugated anti-mouse antibody was obtained from Bio-Rad Laboratories (Munich, Germany), and HRPconjugated anti-rat antibody was purchased from Santa Cruz Biotechnology.
Blood donor, cell isolation, and DC generation negative isolation by use of CD45RO beads and MACS. DCs were generated from isolated CD14 + monocytes, as described previously [13] . Cells were cultured in RPMI 1640 with L-glutamine and supplemented with 10% heatinactivated, pooled human serum and 100 U/ml penicillin-streptomycin (all from Life Technologies).
T cell activation and culture CD3 + T cells were activated, as described before, for CD4 + T cells [14] . In brief, 1 3 10 6 cells/ml freshly isolated CD3 + T cells were cocultured for 
Analysis of T cell proliferation
For determining T cell proliferation by use of the [ For assessing proliferation by use of CFSE dilution assay, isolated T cells were CFSE labeled by use of Vybrant CFDA SE Cell Tracer Kit (Life Technologies) and subsequently activated and treated as described above. Flow cytometric analysis was performed 5 d after culture initiation.
Analysis of apoptosis
Apoptotic cell death was determined by use of flow cytometric analysis of Annexin V-Cy5/7-AAD staining. In brief, T allo were treated for the last 24 h of MLR with the indicated concentrations of DMAG, Akti, Cal, or inhibitor combination. For determination of drug cytotoxicity, unstimulated CD3 + T cells were treated for 24 h with DMAG, Akti, or Cal. Cells were subsequently harvested and stained with Annexin V-Cy5 and 7-AAD (BD Biosciences) for 15 min in 13 Annexin V-binding buffer at room temperature in the dark. Apoptosis of cells was measured and quantified by flow cytometry by use of a FACSCanto. Percentages of specific apoptosis (SA; see equation) were calculated as described previously [15] by use of the following formula:
where A E equals percentage of apoptotic cells in the experimental group, and A C equals percentage of apoptotic cells in the control group. 
Cell-cycle analysis
Immunoblot analysis
To determine phosphorylation of Akt at Ser473 and Thr308, CD3z at Tyr142, and ZAP70 at Tyr319 after short-term stimulation, T cells were preincubated for 30 min with anti-CD3 (5 mg/ml, clone OKT3; Ortho Biotech/JanssenCilag, Neuss, Germany) and anti-CD28 (5 mg/ml, clone L293; BD Biosciences) at 4°C. Subsequently, the indicated concentrations of DMAG, Akti, or Cal were added, and the cells were incubated for 20 min at 4°C. Cells were then activated by crosslinking with goat anti-mouse IgG (20 mg/ml; Dianova, Hamburg, Germany) at 37°C for 5 min. Cell pellets were lysed for 10 min in buffer [50 mmol/l Tris (pH 7.8), 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholat, 60 mM Natriumfluorid, supplemented with 1 tablet Complete Mini protease inhibitor (Roche, Penzberg, Germany)]. Homogenates were centrifuged at 10,000 g for 10 min at 4°C, and the supernatant was used for further analysis. Equal amounts of protein were separated by SDS-PAGE and electrotransferred onto PVDF membranes. After blocking, the membranes were probed with primary antibodies, followed by HRP-conjugated secondary antibodies. Immunoreactive bands were visualized by ECL Western Blotting Substrate (Thermo Fisher, Bonn, Germany).
To determine the effect of DMAG, Akti, Cal, or DMAG/Akti and DMAG/Cal combinations on levels of cell-cycle regulators, cleavage of PARP and C-3, and activation of the Raf/MEK/ERK pathway, T allo were treated for the last 24 h of MLR culture with the indicated concentrations of the inhibitors. Unstimulated and untreated T cells were included as a sample, where indicated. Cells were further processed as described above. 
Analysis of iT regs
Statistical analysis
Statistical analysis was performed by use of Microsoft Excel software (Microsoft, Munich, Germany). Differences between mean values were assessed by use of 2-tailed paired Student's t test. Statistical significance was set at P , 0.05. Calcusyn software (Biosoft, Cambridge, United Kingdom) was used to calculate CI based on the method provided by Chou [16] . CI values ,1 indicate synergism; CI values .1 indicates additivity.
RESULTS
The Akt2 isoform is up-regulated and activated in T allo
First, we examined regulation of the PI3K-dependent kinase Akt in T allo . To activate T allo , we cocultured primary human T cells with allo DCs for 5 d in a primary MLR before immunoblot analysis. As described previously, allogeneic stimulation was accompanied with a strong induction of the Hsp90 isoforms Hsp90a and -b and an up-regulation of Akt expression, whereas expression of proximal TCR signaling molecules CD3z and ZAP70 decreased as a result of internalization and degradation [17] . Further analysis of Akt isoform expression revealed a predominantly increased Akt2 level, whereas the abundance of Akt1 and Akt3 decreased. To assess the activation status of Akt, its phosphorylation at Ser473 or Thr308 residues was determined. Upon allogeneic stimulation, phosphorylation levels at both sites were strongly elevated, suggesting functional activation of Akt via PI3K-dependent mechanisms, in particular, via mammalian target of rapamycin complex 2 (Ser473) or phosphoinositide-dependent kinase 1 (Thr308; Fig. 1 ). The enhanced PI3K/Akt2 signaling activity after allogeneic stimulation proposes that it might be considered as new, potential target for aGvHD treatment.
Hsp90, PI3Kd, or Akt 1/2 inhibition reduces proliferation of T allo
Next, we evaluated the effects of PI3K/Akt2 inhibition compared with Hsp90 inhibition on T allo proliferation. Thereby, the PI3K/Akt2 signaling pathway was targeted at 2 levels: 1) Akt2 by use of Akti, an allosteric inhibitor, which selectively targets both Akt1 and Akt2 but not Akt3 [18] , and 2) PI3Kd, the major PI3K isoform in T cells, with the selective inhibitor Cal [19] . Hsp90 ( Fig. 2A) , Akt 1/2 ( Fig. 2C ), or PI3K ( Fig. 2E ) in T allo were pharmacologically inhibited for the whole MLR culture period of 5 d or for the last 24 h before measuring proliferation rates by [ 3 H]thymidine incorporation. Treatment with the Hsp90 inhibitor DMAG significantly reduced proliferation of T allo by ;60% when treated for the last 24 h of MLR ( Fig. 2A , right) and dose dependently prevented T allo proliferation when inhibitor was added at the beginning of MLR ( Fig. 2A, left) . The targeting of PI3K/Akt by Akt 1/2 or PI3Kd inhibition efficiently prevented T allo proliferation (Fig. 2C , left, and E) when added for the whole MLR culture period and significantly suppressed T allo proliferation by 75% (Akti) or 66% (Cal) when added for the last 24 h of MLR (Fig. 2C , right, and E). Of note, effective Cal concentrations were in a range that has been described previously to additionally target the p110 g, b, and a isoforms of PI3K [20] , suggesting that rather, pan-PI3K inhibition is required for the observed antiproliferative effect. Of note, used concentrations of Cal and Akti demonstrated no cytotoxic effect on unstimulated T cells (Supplemental Fig. 1B and C), whereas higher DMAG (5 mM, 10 mM) concentrations resulted in slight apoptosis induction in nonproliferating T cells (Supplemental Fig. 1A ) [4] . To investigate the molecular effects of pharmacological Hsp90, PI3Kd, or Akt 1/2 inhibition under conditions of short-term stimulation, T cells were preincubated with DMAG, Akti, or Cal for 20 min, subsequently stimulated by CD3/28 cross-linking for 5 min, and analyzed for their Akt phosphorylation at Ser473 or Thr308 residues by immunoblot ( Fig. 2D-F) . Treatment with Akti completely abrogated Akt phosphorylation in CD3/CD28-stimulated T cells (Fig. 2F) . Likewise, phosphorylation of Akt was abolished almost completely upon low-dose Cal treatment. Interestingly, increasing Cal concentrations faintly enhanced phosphorylation of Akt in this short-term experiment, suggesting a redundant role of other PI3K isoforms in Akt activation in T allo (Fig. 2E) . In contrast to PI3Kd or Akt 1/2 inhibition but in line with previous reports [21] , blockade of Hsp90 by DMAG, at least with higher concentrations, enforced phosphorylation of Akt on Ser473 and Thr308 under conditions of short-term stimulation (Fig. 2D ). However, longer incubation of T allo with DMAG for 48 h clearly reduced phospho-Akt at Thr308 and Akt abundance, demonstrating effective Hsp90 inhibition-induced degradation of activated Akt in T allo (Supplemental Fig. 1D ). To explore the effect of Hsp90, PI3Kd, or Akt 1/2 inhibition on TCR signaling, we also investigated the phosphorylation status of CD3z and ZAP70. Preincubation with DMAG clearly reduced phosphorylation of well-known Hsp90 substrate protein ZAP70 on Tyr319 [22] , whereas there was no substantial difference in phosphorylation of CD3z. Inhibition of PI3Kd or Akt 1/2 , in contrary, increased phosphorylation of CD3z and ZAP70 on Tyr142 and Tyr319, presumably by a yet-unknown, counter-regulatory mechanism (Fig. 2D-F) .
Combined Hsp90/Akt 1/2 and Hsp90/PI3Kd inhibition synergistically suppresses T allo proliferation Next, we evaluated the effects of concomitant inhibition of Akt 1/2 and Hsp90 or of PI3Kd and Hsp90 on T allo proliferation. T allo were incubated with Akti or Cal, alone or in combination with DMAG for the whole MLR culture period (Fig. 3A and B , left, Prevention of T allo proliferation) or alternatively, for the last 24 h of MLR culture (Fig. 3A and B , right, Treatment of T allo proliferation) before assay proliferation by quantifying [ 3 H] thymidine incorporation. Treatment with both drug combinations significantly prevented and decreased T allo proliferation compared with single drug use (Fig. 3) . To quantify further the antiproliferative effects of the combination approaches, we used the Calcusyn software to calculate their CI, according to the method of Chou [16] . With 1 exception, these analyses revealed CI values ,1 for the effect levels calculated, indicating synergy of both drug combinations (Tables 1 and 2) . Remarkably, PI3Kd-selective Cal concentrations of 5 and 10 mM were completely sufficient to cause this combinatorial effect on T allo proliferation. Taken together, our data demonstrate that simultaneous inhibition of the PI3Kd/Akt 1/2 pathway and the molecular chaperone Hsp90 synergistically suppresses proliferation of T allo . 
Primary human CD3
+ T cells were stimulated or not for 5 d with allo DCs (MLR). Then, levels of Akt, Hsp90 isoform, CD3z, and ZAP70 and the phosphorylation status (p) of Akt at Ser473 and Thr308, CD3z at Tyr142, and ZAP70 at Tyr319 in whole-cell lysates were determined by immunoblot analysis with actin as a loading control. Immunoblots were performed at least in triplicate with consistent results.
The antiproliferative effect of the combined Hsp90/Akt 1/2 and Hsp90/PI3Kd inhibition is caused by cell-cycle arrest and induction of apoptosis
To elucidate underlying mechanisms of the detected synergistic effect of simultaneous Hsp90/Akt 1/2 and Hsp90/PI3Kd inhibition on T allo proliferation, we analyzed apoptosis and cell-cycle regulation. T allo cells were incubated with selected concentrations of Cal or Akti, alone or in combination with DMAG, for the last 24 h of MLR culture, and apoptosis was assayed by Annexin V/7-AAD staining, as described previously [14] . The apoptotic cell fraction was accounted for ;7% upon Akt 1/2 inhibition, 3% upon PI3Kd inhibition, and 20% upon Hsp90 inhibition. Concomitant inhibition of Akt 1/2 or PI3Kd further enhanced the DMAG-induced apoptotic effect by ;5% (Fig. 4A and B) . In line with this observation, immunoblot analysis showed increased cleavage of the characteristic apoptosis marker C-3 and its substrate PARP after concomitant Hsp90/Akt 1/2 or Hsp90/PI3Kd inhibition ( Fig. 5A and B) . Contrastingly, used concentrations of DMAG/Akti (Supplemental Fig. 1E ) and DMAG/Cal (Supplemental Fig. 1F ) demonstrated no cytotoxic effect on unstimulated T cells. However, the pronounced inhibitory effect of the combined PI3Kd/Akt 1/2 and Hsp90 blockade on T allo proliferation can hardly be explained by the relatively small fraction of apoptotic cells. In a next step, therefore, we analyzed cell-cycle regulation in proliferating primary T cells. To obtain an adequate number of cells in cell cycle, primary human T cells were physiologically activated by CD3/CD28-coated beads for 3 d and treated with Akti, Cal, or DMAG alone or DMAG/Akti and DMAG/Cal combinations for the last 24 h. Based on subsequent determination of the DNA content by bivariate BrdU/PI staining, the cell-cycle analysis revealed that PI3Kd and Akt 1/2 blockade promotes an accumulation of cells in the G1 phase, whereas Hsp90-inhibited T cells additionally exhibited a G2/M-phase arrest and a reduced S phase. Combinatorial inhibition of Hsp90/Akt 1/2 or Hsp90/PI3Kd further reduced the cell fraction in the S phase, whereas cells in the G1 phase were only faintly increased (Fig. 4C and D and . Importantly, furthermore, abundance of DMAG-induced p53 was strongly enhanced by concomitant Cal treatment (Fig. 5C and D) . As also shown in Fig. 5C and D, Rb, another key regulator of the progression from G1 to S phase, is strongly expressed and phosphorylated in T allo cells. Expression and phosphorylation of Rb in T allo cells were efficiently suppressed by pharmacological Hsp90 inhibition, thus confirming Rb as a downstream target of the Hsp90-dependent client proteins CDK2 and CDK4. Likewise, the previously described dependence of Rb on PI3K/Akt signaling [23] was also proven by our observation that pharmacological inhibition of Akt 1/2 or PI3Kd attenuated Rb phosphorylation and expression. Combined inhibition of Hsp90/Akt 1/2 or Hsp90/PI3Kd further reduced Rb expression and phosphorylation compared with a single drug treatment, providing a possible explanation for the observed S-phase decline in CD3/CD28-activated T cells caused by a combination treatment (Fig. 4C and D) . Our results imply that besides the moderately increased apoptosis, the synergistic, antiproliferative effect of simultaneous Hsp90/Akt 1/2 or Hsp90/ PI3Kd inhibition in T allo cells is a result of regulation of central cell-cycle regulators, leading to cell-cycle arrest. To investigate the influence of concomitant Hsp90/Akt 1/2 inhibition on the Raf/MEK/ERK pathway, we examined expression of Raf1 and phosphorylation state of downstream MAPKs MEK and ERK by compartment was measured by use of flow cytometry. LAP has recently been reported as a specific marker for the identification of activated antigen-specific T regs [27, 28] , in which cellsurface expression correlates with suppressive function of T reg [29] . We observed increased percentage of iT regs after treatment with Akti, low to medial dose of DMAG (0.01 mM; 0.05 mM DMAG), or the combination of both. Similar results were obtained by inhibiting PI3Kd alone or in combination with Hsp90 ( Fig. 6A and Supplemental Fig. 2A) (Fig. 6B) . Of note, with the use of 3rd-party DCs, different from the DCs used for the iT reg isolation, we observed a lowered suppressive capacity of iT regs , indicating an antigen-specific, suppressive activity of isolated iT reg (Supplemental Fig. 2B ).
In contrast to the above-described, long-term anti-PI3Kd/Akt 1/2 and/or Hsp90 approaches (4 d of MLR culture), a limited drug exposure time of only 24 h at the last MLR culture day was (Fig. 6C) . These 2 factors have been demonstrated previously to be essential for T reg activation [24, 30] . Hence, induction of functional active T regs provides a possible explanation for the distinctive suppressive effect on T allo proliferation in MLR exposed for the whole MLR culture period to Akt 1/2 , PI3Kd, and low-tomedium Hsp90 inhibitor concentrations, alone and in combination ( Fig. 3A and B, left) .
Combined inhibition of Hsp90/Akt 1/2 or Hsp90/PI3Kd impairs vitality and decreases costimulatory molecule expression of mature DCs
In addition to their role in T cells, Hsp90 and PI3K/Akt activity has been reported to critically contribute to survival and function of DCs [31, 32] . To prove if combined inhibition of Hsp90/PI3Kd or Hsp90/Akt 1/2 also impairs function of allo DCs in MLR, we determined vitality of allo DC (Fig. 7A) and expression of costimulatory molecules CD40 and CD86 ( Fig. 7B and C) on the cell surface of allo DC after incubation with Akti or Cal, with or without concomitant DMAG treatment for 2 d. Although inhibition of Akt 1/2 reduced vitality of allo DC, we could not observe an effect on surface expression of costimulatory molecules. PI3Kd and Hsp90 inhibition alone had no influence on vitality of allo DC but faintly decreased expression of CD40 and CD86. Combined inhibition of Hsp90/PI3Kd or Hsp90/Akt 1/2 significantly decreased vitality of allo DCs in MLR and noticeably attenuated cell-surface expression of CD40 and CD86 (Fig. 7A-C) . These results imply that synergistically reduced proliferation of T allo in response to simultaneous Hsp90/PI3Kd or Hsp90/Akt 1/2 might be partly explained by an additional effect of drug combinations on vitality and phenotype of allo DCs in MLR. Combined Hsp90/Akt 1/2 inhibition targets activation of CD4 + and CD8 + T allo but preserves immunity against viral pathogens Current aGvHD therapies use immunosuppressive drugs that affect activation of T allo , as well as pathogen-specific T cell responses. Therefore, we asked whether Akt 1/2 inhibition alone or in combination with Hsp90 inhibition might preserve antiviral immunity. As reactivated or newly acquired CMV frequently causes severe infections after ASCT, we used T cells of CMV-positive, HLA-A*0201 + blood donors and stimulated them with allo DCs in primary MLR, in the presence of Akti, DMAG, or a combination of both. The percentage of CMVspecific T cells was determined, measuring CMV-specific CD8 + T cells with a MHC I pentamer that specifically recognizes the CMVpp65-derived, HLA-A*0201-bound epitope NLV. As shown in Fig. 8A and Supplemental Fig. 3A , we observed that neither Akt nor Hsp90 inhibition alone or their combination had any impact on the fraction of CMVpp65-specific CD8 + T cells. To evaluate the capability of the CMVpp65-specific T cells to respond to antigen, inhibitor-treated cells were rechallenged with autologous DCs, pulsed with a CMVpp65-specific peptide pool. In addition, we further proved the successful depletion of T allo by restimulation of inhibitor-treated T cells with the same allo DCs as used for the primary stimulation and determined proliferation. Furthermore, supernatants of restimulated cultures were collected, and the amount of secreted IFN-g was measured by use of the CBA technique. We found that Hsp90 inhibition reduced IFN-g production and proliferation of restimulated T allo , whereas Akt 1/2 inhibition lacked effects on T allo ( Fig. 8B and C) . In contrast, the combination of Akt 1/2 with Hsp90 inhibition diminished proliferation and IFN-g production of restimulated T allo to a degree comparable with that caused by treatment with high DMAG concentrations. Of note, simultaneous Hsp90/Akt 1/2 inhibition also affected IFN-g production of CMV-specific T cells to a similar extent as treatment with high DMAG concentrations, although to a significant lower degree than IFN-g production of T allo . This is probably a result of the fact that Hsp90 inhibition alone and in combination with Akt 1/2 inhibition reduced surface expression of CD8 (mean) on CMV-specific CD8 + T cells after 5 d exposure to DMAG (Supplemental Fig. 3B ), potentially resulting in a reduced IFN-g production capability after restimulation with pp65-pulsed autologous DCs [33] . We also observed that Hsp90 inhibition preferentially affects CD4 + T allo activation and a proliferative response compared with CD8 + T allo , as determined by measuring expression of the IL-2Ra chain CD25 on T allo , incubated for the whole MLR culture with DMAG. In addition, we found that the proportion of proliferative CD8 + T allo cells increased to the disadvantage of proliferative CD4 + T allo cells in response to Hsp90 inhibition, resulting in a significant decreased CD4 + /CD8 + ratio. In contrast, treatment of the MLR culture with the DMAG/Akti combination comparably reduced CD25 expression on CD4 + and CD8 + T allo . Furthermore, the DMAG/Akti and DMAG/Cal combination inhibited proliferation of CD4 + and CD8 + T allo , causing a slightly increased CD4 + /CD8 + ratio, indicating a more balanced effect of drug combination on CD4 + and CD8 + T allo ( Fig. 8D and E and Supplemental Fig. 4 ). Taken together, our results indicate that combined Hsp90/Akt 1/2 and Hsp90/PI3Kd inhibition ensures an even depletion effect on CD4 + as well as on CD8 + T allo but preserves an anti-CMV immune response after T allo depletion.
DISCUSSION
Unselected T cell depletion is clinically associated with increased rates of opportunistic infections and recurrence of the malignant disease [34] . Although experimental evidence suggests the existence of different T cell clones capable of distinguishing between GvL and aGvHD antigens, selective modification of different T cell effects after ASCT still remains a major challenge. Thus, it is highly desirable to develop therapeutic strategies that attenuate the induction of the harmful aGvHD while sparing the beneficial GvL activity, as well as pathogen-specific immune responses. The molecular chaperone Hsp90 might represent a reasonable therapeutic target for depletion of T allo , as well as tumor cells. Thus, we have previously shown that Hsp90 inhibition reduces T allo proliferation without affecting antiviral T cell immunity [4] . In addition, aberrantly up-regulated Hsp90, promoting tumor cell survival and growth, has been described in human hematologic malignancies. such as MM [35] , chronic lymphocytic leukemia [22] , acute lymphoid leukemia [36] , acute myeloid leukemia [37] , and diffuse large B cell lymphoma [38] -altogether, malignancies that are subject to ASCT. This implicates that pharmacological Hsp90 inhibition could serve as a bridging concept to suppress residual tumor growth temporally upon ASCT until the GvL reaction has been fully developed. However, first results from clinical anti-cancer trials revealed only limited clinical efficacy if pharmacological Hsp90 inhibitors were applied as monotherapy, indicating the need of combination approaches [39] . We hypothesized that Akt and its upstream regulator PI3K might represent potential combinatorial targets for Hsp90 inhibition, as Akt has been well [10, 20, [40] [41] [42] . In addition, PI3K/Akt signaling has reported to be critically involved in the regulation of cell cycle and survival of activated T cells [6] . Here, we observed an up-regulation of Akt expression in T allo , which can predominantly be attributed to pronounced expression of the Akt2 isoform, indicating a nonredundant, specific role of Akt isoforms in T allo . Inhibition of Akt by the allosteric Akt1 and Akt2 isoform-specific inhibitor Akti caused a G1 cell-cycle arrest and drastically decreased proliferation of T allo . However, restimulation experiments revealed that drug removal and subsequent allogeneic restimulation release T allo from G1 arrest, indicating that the Aktimediated effect on cell-cycle progression is reversible. In line with the Akti results, functional inhibition of PI3Kd by use of the specific pharmacological PI3Kd inhibitor Cal also reduced T allo proliferation. Thereby, a relatively high Cal concentration, which has been described previously to broaden the PI3Kd inhibitory effect also on the other PI3Kd [20] , was necessary to achieve a considerable suppression of T allo proliferation, indicating that selective PI3Kd inhibition might be compensated, at least in parts, by activity of other PI3Kd, as already demonstrated for antigen-mediated cytokine production and proliferation of T cells [43, 44] . Taken together, our results demonstrate an impact of PI3K/Akt activity on T allo proliferation in vitro but also indicate that neither Akt 1/2 nor PI3Kd inhibition alone might be sufficient for a substantial depletion of T allo in aGvHD patients and thus, suggest combination approaches.
Here, we evaluated the combination approach with concomitant Hsp90 and PI3Kd or Akt 1/2 blockade and observed enhanced T allo depletion as a result of a synergistic, inhibitory effect on T allo proliferation. In contrast to single PI3Kd or Akt 1/2 inhibition, proliferation of the combination-treated T allo remained suppressed when restimulated with allo DCs. In addition, upon allogeneic restimulation, we observed reduced secretion of IFN-g, indicating that the Hsp90/PI3K/Akt combination approach also critically impairs T allo function. Further analysis of the antiproliferative effect revealed that combined treatment of T allo with Hsp90 and PI3Kd or Akt 1/2 inhibitors arrested cell-cycle progression involving the central cell-cycle regulators p21 WAF1/CIP1 , p27 Kip1 , p53, and Rb, which have been described previously to be controlled directly or indirectly by PI3K/Akt or HSP90, respectively [45] [46] [47] [48] . In addition, we detected C-3 activation and PARP cleavage, along with increased apoptosis rates. Thus, our findings suggest that cell-cycle arrest and induction of apoptosis contribute to the antiproliferative effect upon combined Hsp90/PI3Kd/Akt 1/2 inhibition.
TCR engagement results in activation of signal transduction cascades, including phosphorylation of MEK and ERK via Raf1 [8] . The ERK pathway has been reported to play a crucial role in the regulation of T cell activation differentiation, proliferation, and survival [49, 50] . We observed that combined Hsp90/Akt 1/2 inhibition dampened even further the already, slightly reduced activation of the Raf/MEK/ERK pathway in T allo by Hsp90 + was determined by use of flow cytometry, as described in Materials and Methods. (E) CD4/CD8 ratio was calculated by use of Microsoft Excel. Data are given as means 6 SEM of 10 independent experiments. **P , 0.01; ***P , 0.001. inhibition, offering an additional, possible explanation for the synergistic effect on T allo proliferation. As it has been reported that CD4 + and CD8 + T cells play critical roles in the pathogenesis of aGvHD, we monitored the fate of both populations and found that single Hsp90 inhibition faintly skewed the CD4/CD8 ratio by preferentially suppressing the activation and proliferation of CD4 + T allo . This result indicates a higher sensitivity of CD4 + T cells to Hsp90 inhibition, presumably because of stronger Hsp90 induction in activated CD4 + T cells compared with activated CD8 + T cells [4] . Contrastingly, combined
Hsp90/PI3Kd/Akt 1/2 inhibition led to comparable reduction of CD4 + and CD8 + T allo activation, suggesting that the combination approach is capable of blocking essential signaling pathways in CD4 + , as well as in CD8 + T cells. Our findings support the widely accepted notion that equal suppression of CD4 + and CD8 + T allo is required for sufficient prevention of aGvHD [51] . In addition to their role in T cells, Hsp90 and PI3K/Akt activity has been reported to contribute critically to survival and function of DCs [31, 32] . We found that combinatorial inhibition of Hsp90/PI3Kd/Akt 1/2 reduced vitality of DCs in MLR on the one hand and also impaired cell-surface expression of essential costimulatory molecules on vital DCs. Thus, DCs surviving Hsp90/PI3Kd/Akt 1/2 treatment resemble immature DCs, which are capable of inducing and controlling transplant tolerance by, among others, inducing T regs [52] . Thus, concomitant targeting of Hsp90/PI3K/Akt inhibition could additionally reduce aGvHD by affecting host and donor DCs, which both play a major role for initiation and maintenance of aGvHD [53] . In accordance with our data in T cells, also in cancer therapy, experimental as well as first clinical evidence indicate that PI3K/Akt inhibitors should be combined with other anti-cancer agents to induce substantial apoptosis [54] [55] [56] [57] [58] . Therefore, it would be intriguing to evaluate if a combinatorial inhibition of Hsp90/PI3K/Akt is capable of reinforcing this cytotoxic effect in different hematologic malignancies, as shown already for MM [11, 12] . Thus, early administration of Hsp90/PI3K/Akt combinations in the critical, early interval after ASCT may not only eliminate T allo but also, may eradicate residual malignant cells resistant to transplant conditioning and thereby, contribute to protection of disease relapse.
Increasing experimental evidence suggests that T regs , which are crucial for the development of transplantation tolerance, can reduce aGvHD after ASCT [59, 60] . Conversely, it has been shown previously that removal of CD4 + CD25 + T regs aggravated aGvHD [61, 62] . Thus, procedures that preserve or even increase the number of T regs to alleviate aGvHD are highly warranted. Recently, it has been demonstrated that treatment with the hypomethylating agent 5-Azacitidine increases percentage of T regs and thus, mitigates aGvHD by simultaneously preserving the GvL effect [63, 64] . Herein, we demonstrate that pharmacological inhibition of Akt 1/2 , PI3Kd, and Hsp90 (at low concentrations), alone or in combination, induces CD4 + CD25 + CD127 dim Foxp3 + LAP + T regs in a MLR. In accordance with our data, it has been reported previously that a dampened Akt activity (especially Akt 2 activity) is necessary for T reg induction and maintenance of their suppressive function [65, 66] . Furthermore, it has been demonstrated that Hsp90-mediated Hsp70 induction is necessary for promoting T reg survival and suppressive function. Strikingly, CD4 + CD25 + LAP + iT regs demonstrated high suppressive and antigen-specific capacity, substantiating a recent report describing LAP + expression on CD4 T cells as a reliable marker for the identification of antigenspecific T regs [28] . Furthermore, Mahalingam et al. [67] demonstrated that isolated CD4 + CD25 + LAP + showed higher suppressive activity than CD4 + CD25 + LAP 2 , underscoring the use of LAP expression for identification of a potent, suppressive subgroup of T regs . In mouse studies, CD4 + LAP + T regs have also been shown to suppress murine autoimmunity in experimental models of encephalomyelitis, arthritis, lung allergic inflammation, arthritis, and atherosclerosis [68] [69] [70] [71] Other key players in T reg development are the FoxO transcription factors that are negatively regulated via the PI3K/Akt pathway by Akt-mediated phosphorylation [30] . Accordingly, we observed enhanced down-regulation of phosphorylated FoxO1/3a upon combined Hsp90/Akt 1/2 inhibition compared with single Akt 1/2 and Hsp90 inhibition. In addition, we detected induction of Hsp72 upon single Hsp90 and combined Hsp90/Akt 1/2 inhibition, which is a well-known class effect of Hsp90 inhibitors [72] . It has previously been hypothesized that correct folding of newly synthesized FoxP3 is executed by interaction with Hsp72, thereby supporting function and survival of T regs [24] . Thus, dephosphorylated FoxO1/3a and up-regulated Hsp72 create an ideal precondition for T reg induction. Hence, we assume that induction of functional, active T regs represents another powerful mechanism that is mediated by the Hsp90/PI3K/Akt combinatorial inhibition approach. We are fully aware that the immunosuppressive effects of Hsp90/PI3K/Akt inhibition might also impair the allograft-mediated GvI effect, thus enhancing the rate of opportunistic infections caused by viral and fungal pathogens, such as CMV, EBV, Candida albicans, and Aspergillus fumigatus [73] [74] [75] . However, we observed that antiHsp90/Akt 1/2 treatment of MLR cultures preserved the frequencies of CMV-specific CD8 + T cells, which compared with the DMSO-treated control, responded almost equally to restimulation with CMVpp65-peptide pool-pulsed DCs. In a recent study, incubation of human CD3 + T cells with Hsp90 inhibitor geldanamycin for 24 h caused reduced expression of essential T cell surface antigens, such as CD3, CD4, CD8, and CD28, which can result in a weakened activation of T cells when rechallenged with antigen [76] . Likewise, we also observed a reduced surface expression of CD8 (mean) on CMV-specific CD8 + T cells after 5 d exposure to DMAG, alone and in combination with Akti (Supplemental Fig. 6 ), potentially resulting in a reduced IFN-g production capability after restimulation with pp65-pulsed, autologous DCs [33] . Thus, our results indicate that the resting T cells, including memory T cells specific for CMVpp65, survive and were only slightly, functionally compromised by previous Hsp90/Akt 1/2 inhibition.
Furthermore, it has been demonstrated that Hsp90 inhibitors have strong antifungal activity by preventing the emergence of resistance against echinocandin and azole drugs, 2 classes of antifungal drugs that are widely used for treatment against C. albicans and A. fumigatus infection [77, 78] . Moreover, it has been shown that Hsp90 and the PI3K/Akt pathway are critical for replication of CMV and survival of EBV-infected cells
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